Seattle Genetics is Washington’s largest biotech company, and is slowly but surely moving to the big pharma league. It is valued at almost $10 billion, and has 900 employees and plans to increase the number to 1,100. The company was founded in 1998 by Clay Siegall, who is currently its CEO. It has done extensive research on oncology and cancer treatment, and has been studying human antibodies to find out how they can be used to fight cancer.

 

Seattle Genetics has 11 cancer drugs in the works, 4 of which are likely to be released into the market soon. These 4 are in the final stages of testing. One of these is Adcetris, which is being tested for use as a front-line drug in the treatment of Hodgkin lymphoma, a type of cancer which affects the lymphatic system. Adcetris has already been approved by the FDA for use by patients whose first or second drugs are not effective. Projected annual sales from it are $1 billion if it is approved as a front-line treatment. Seattle Genetics is also doing research on the possibility of using Adcetris in combination with Opdivo, a type of checkpoint inhibitor used in immunotherapy. The other 3 drugs are for the treatment of bladder cancer, breast cancer, and acute myeloid leukemia. The approval of these drugs will be a huge step in the treatment of these types of cancer.

 

About Clay Siegall

Clay Siegall has extensive experience in the biopharmaceutical industry and is very passionate about the fight against cancer. Under his leadership, Seattle Genetics has played a great role in advancements in the treatment against cancer. His secret to success is diversification. Unlike other biotech companies which focus all their energies on one or two drugs and end up crumbling if they are not approved, he does extensive research on different types of cancer and the existing treatment options. This enables him to produce more effective drugs. He also learns from industry authorities and tries to emulate some of their business models in Seattle Genetics. This is how Clay Siegall ensures that Seattle Genetics remains relevant in the industry.

 

Conclusion

Clay Siegall is committed to the fight against cancer, and this is what gives him the motivation to keep researching and producing cancer drugs. He acknowledges that it is not easy but nothing will stop him. Thanks to his visionary leadership, Seattle Genetics has made huge strides in the treatment of cancer and continues to forge on despite the numerous challenges in the industry.

 

Comments closed.